Biosceptre International

biosceptre international is a private, unlisted biotechnology company based in cambridge, united kingdom that is developing and commercializing antibody technologies to address a wide range of applications in the diagnosis and treatment of cancer. biosceptre’s technology is centered on p2x7, specifically nf-p2x7, a form of the receptor in which a critical function, the formation of a large transmembrane pore on prolonged activation, has been lost. this loss in function is important in mediating key aspects of the receptors involvement in the transition of cells to a cancerous state. to date, biosceptre has demonstrated nf-p2x7 is present in over 20 forms of cancer and counting. the company has developed antibodies that interact with nf-p2x7 in a manner that leads to the death of cancer cells and biosceptre believes this approach has the potential to provide an effective therapeutic against many forms of cancer. in addition identification of the nf-p2x7 receptor on tissues has diagn